Description

Wave Life Sciences Ltd. (WVE) is a clinical-stage genetic medicine firm dedicated to inventing, refining, and manufacturing novel stereopure oligonucleotide therapies. The company utilizes its proprietary PRISM platform for discovery and drug development. These specialized oligonucleotides are designed to interact with ribonucleic acid (RNA) to precisely modulate protein expression within the body. This involves either diminishing the production of disease-causing proteins, restoring the synthesis of functional proteins, or generally adjusting protein levels as needed. The company's pipeline includes several key programs targeting neurological disorders. WVE-004, a C9orf72 molecule, is being developed for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). WVE-003 focuses on the mutant huntingtin SNP3 molecule for Huntington's disease, while WVE-N531 targets Exon 53 for Duchenne muscular dystrophy. Additionally, ATXN3 is an early-stage program addressing spinocerebellar ataxia 3, complemented by multiple other preclinical initiatives for central nervous system (CNS) conditions. Beyond CNS applications, Wave Life Sciences is also developing GalNAc-conjugated AIMers for various hepatic indications, including Alpha-1 antitrypsin deficiency (AATD). Their preclinical efforts extend to ocular diseases, with programs for Usher syndrome type 2A (USH2A) and retinitis pigmentosa caused by a P23H mutation in the RHO gene (RhoP23H). Wave Life Sciences actively collaborates with a diverse array of partners, such as pharmaceutical companies like Pfizer Inc. and Takeda Pharmaceutical Company Limited, alongside academic and research institutions including the University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A., University of Louisville, and University College London. Established in 2012, the company is headquartered in Singapore.